- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Extraskeletal myxoid chondrosarcoma.
Displaying page 1 of 1.
| EudraCT Number: 2013-005456-15 | Sponsor Protocol Number: GEIS-32 | Start Date*: 2014-05-07 |
| Sponsor Name:Grupo Español de Investigación en Sarcomas | ||
| Full Title: A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) | ||
| Medical condition: Patients with unresectable, locally advanced or metastatic solitary fibrous tumor (SFT) or extraskeletal myxoid chondrosarcoma (EMC) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) IT (Completed) FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-008513-19 | Sponsor Protocol Number: SAHA-I | Start Date*: 2009-12-01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:University Hospital Heidelberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen. English title: A Phase II Study to Investigate the Efficacy... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects suffering from advanced, metastatic soft tissue sarcoma. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-024518-74 | Sponsor Protocol Number: IPI-926-04 | Start Date*: 2011-06-14 | |||||||||||
| Sponsor Name:Infinity Pharmaceuticals, Inc | |||||||||||||
| Full Title: A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma | |||||||||||||
| Medical condition: Metastatic or Locally Advanced Chondrosarcoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) SE (Completed) DE (Completed) NO (Completed) NL (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-003940-30 | Sponsor Protocol Number: NO21157 | Start Date*: 2008-05-14 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarc... | |||||||||||||
| Medical condition: Ewing’s sarcoma and other sarcoma subtypes | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004040-10 | Sponsor Protocol Number: GEIS-52 | Start Date*: 2017-02-24 |
| Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
| Full Title: Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas | ||
| Medical condition: Soft tissue sarcoma (undifferentiated pleomorphic sarcoma, synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, angiosarcoma, epithelioid hemangiosarcoma, solitary fibrous tumor and ep... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002821-28 | Sponsor Protocol Number: ET20-128 | Start Date*: 2020-12-24 |
| Sponsor Name:Centre Léon Bérard | ||
| Full Title: RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma o... | ||
| Medical condition: Metastatic or unresectable advanced rare sarcomas | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-014889-26 | Sponsor Protocol Number: EORTC 62091 | Start Date*: 2011-12-15 | |||||||||||
| Sponsor Name:EORTC (European Organisation for Research and Treatment of Cancer) | |||||||||||||
| Full Title: TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Ti... | |||||||||||||
| Medical condition: Histologically proven advanced and/or metastatic malignant soft tissue sarcoma intermediate/high grade, excluding the following tumor types : Well-differentiated liposarcoma Embryonal rhabdomyo... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) BE (Completed) HU (Completed) DK (Completed) AT (Completed) NL (Completed) SK (Completed) ES (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002468-18 | Sponsor Protocol Number: EZH-102 | Start Date*: 2016-02-19 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Atypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features. Epithelioid sarcoma, Epithelioid malignant peripher... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-000522-58 | Sponsor Protocol Number: NPM001 | Start Date*: 2014-10-02 | |||||||||||
| Sponsor Name:Klinikum der Universität München | |||||||||||||
| Full Title: A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or ad... | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002469-41 | Sponsor Protocol Number: EZH-202 | Start Date*: 2016-04-18 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Cohort 1: Rhabdoid tumors (malignant rhabdoid tumors, rhabdoid tumors of the kidney, atypical teratoid rhabdoid tumors, and selected tumors Cohort 2: Relapsed/refractory synovial sarcoma with SS18... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-001186-20 | Sponsor Protocol Number: GEIS-83 | Start Date*: 2021-10-22 |
| Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS | ||
| Full Title: Phase Ib/II multicohort trial of different schemes of PM14 in monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors | ||
| Medical condition: Advanced soft tissue sarcoma and other solid tumors | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-001951-39 | Sponsor Protocol Number: ST1481-DM-04-004 | Start Date*: 2005-12-14 | |||||||||||
| Sponsor Name:SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | |||||||||||||
| Full Title: "Estudio fase II de Gimatecan (ST1481) como tratamiento de rescate en pacientes con sarcoma de partes blandas avanzado o metastático y recidivados después de un régimen de quimioterapia basado en a... | |||||||||||||
| Medical condition: sarcoma de partes blandas avanzado o metastático | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) IT (Completed) DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-004984-35 | Sponsor Protocol Number: EZH-501 | Start Date*: 2016-08-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects will receive tazemetostat as dictated in their antecedent study. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) BE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
